|Day Low/High||0.23 / 0.24|
|52 Wk Low/High||0.18 / 0.35|
Dendritic cancer vaccines are too weak to be effective.
Investors in Northwest Biotherapeutics Inc saw new options become available this week, for the July 2014 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Biotech columnist Adam Feuerstein answers readers' questions about healthcare companies.
Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.
A critique of Smith's critique of my bearish view of Northwest Bio and its brain tumor therapy.
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
Standard & Poor’s announced today that it has commenced Factual Stock Report coverage on Northwest Biotherapeutics.
Northwest Biotherapeutics (OTCBB: NWBO) reminded markets, in response to recent investor concerns about Dendreon’s Provenge immune therapy, that NWBT’s DCVax® immune therapies for a broad range of cancers...
Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has expanded its number of clinical trial sites, and now has 12 sites across the U.
Northwest Biotherapeutics (OTCBB:NWBO) ("NWBT") announced today a $4.
Northwest Biotherapeutics (OTCBB: NWBO) today announced that it has made changes and substantially expanded its management team, adding several highly experienced executives.
Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has put in place a series of financing arrangements, including a $3 million investment already received, and access to up to $25 million of further ...
Northwest Biotherapeutics (OTCBB:NWBO) today announced that it has accelerated the addition of clinical trial sites, exceeding its projections for the doubling of such sites across the U.
Northwest Biotherapeutics (OTCBB:NWBO) announced today that it is partnering with Fraunhofer for production of DCVax®-L for brain cancer, for clinical trials and compassionate use cases in Europe.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.